Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07275190

The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome

Led by Fondazione IRCCS Policlinico San Matteo di Pavia · Updated on 2025-12-10

60

Participants Needed

1

Research Sites

13 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying patients with eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) to collect clinical, laboratory, and instrumental data. The goal is to use artificial intelligence to identify characteristics that differentiate these two diseases and predict how patients might respond to treatment. This study aims to improve diagnosis and treatment decision-making for these conditions. Participants will undergo blood draws for laboratory assessments as part of the study procedures. These data will be analyzed using machine learning techniques to find meaningful differences between EGPA and HES. The study focuses on gathering information rather than testing a new drug or treatment. During the study, participants will provide clinical and laboratory data, including blood samples. Researchers will monitor these data over an 18-month period to identify distinct disease features. The study involves no masking or placebo, and participants will be followed to assess characteristics that separate the two conditions. The total participation time corresponds to the data collection period of 18 months.

CONDITIONS

Brief Title

The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or over
  • A diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome (HES)
  • Willing and able to give informed written consent, or permission for a nominated friend or relative to provide written consent if unable due to physical disabilities
Not Eligible

You will not qualify if you...

  • Lack of a confirmed diagnosis of EGPA or HES
  • Presence of other causes of eosinophilia

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Trial Site Locations

Total: 1 location

1

Fondazione IRCCS Policlinico San Matteo, SC Reumatologia

Pavia, Italy, 27100

Actively Recruiting

Loading map...

Research Team

C

Carlomaurizio Montecucco

A

Alessandra Milanesi

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

0

Similar Trials

Impact of Mepolizumab Treatment on the Nasal Microbiome and ...

EGPA - Eosinophilic Granulomatosis With Polyangiitis

Actively Recruiting

1 location

Prospective Registry of Eosinophilia With Respiratory Manife...

Eosinophilic Asthma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here